GNA11 Q209L

CI-VAR-00003516Explore in graph →CIViC 4413

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
NF1 Mutation OR GNA11 Q209L	Trametinib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID12027 In this phase 2 clinical trial, 50 patients were treated with trametinib, a MEK1/2 inhibitor. Among them, 46 had tumours harbouring NF1 mutations (S1 protocol), while 4 had non-uveal melanomas harbour… (full text at CIViC) PMID 37053535 · Wisinski et al., 2023 · Open in CIViC	civic
Unmapped disease1unmapped disease
GNA11 Q209L	(functional)	Functional	D	Supports Gain Of Function	3	accepted	EID11150 Western blots of transfected HEK293 cells showed that GNA11 Q209L had increased phosphorylation of the ERK, p38 MAPK, and JNK pathways, indicating activation (p<0.05). Zebrafish expressing Q209L showe… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.